Acquisition of Fas resistance by Fas receptor mutation in a childhood B-precursor acute lymphoblastic leukemia cell line, MML-1

International Journal of Oncology

Volumn 27, Issue 2, 2005, Pages 573-579

  Inaba, Hiroto ^a,b,d   Shimada, Keiji ^c   Zhou, Yan Wen ^a   Ido, Masaru ^a   Buck, Steven ^b   Yonehara, Shin ^a   Kaplan, Joseph ^b   Komada, Yoshihiro ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KYOTO UNIVERSITY   (Japan)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

All; Childhood; Fas; Mutation

Indexed keywords

ANTINEOPLASTIC AGENT; CASP3 PROTEIN, HUMAN; CASP8 PROTEIN, HUMAN; CASPASE; CASPASE 3; CASPASE 8; CD15 ANTIGEN; CD19 ANTIGEN; ETOPOSIDE; FADD PROTEIN, HUMAN; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; MONOCLONAL ANTIBODY; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ACUTE LYMPHOCYTIC LEUKEMIA; AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CHILD; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; ENZYME ACTIVATION; FLOW CYTOMETRY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROTEIN BINDING; TUMOR CELL LINE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD15; ANTIGENS, CD19; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CASPASE 3; CASPASE 8; CASPASES; CELL LINE, TUMOR; CHILD; DNA MUTATIONAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ETOPOSIDE; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LEUKEMIA, PRE-B-CELL; MUTATION; PROTEIN BINDING;

EID: 33644688960     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.2.573     Document Type: Article

References (36)

1. Yonehara S. Ishii A and Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169: 1747-1756. 1989.
2. ltoh N. Yonehara S. Ishii A. Yonehara M. Mizushima S. Sameshima M. Hase A. Seto Y and Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66: 233-243, 1991.
3. Takahashi T. Tanaka M. Inazawa J. Abe T. Suda T and Nagata S: Human Fas ligand: gene structure, chromosomal location and species specificity. Inl Immunol 6: 1567-1574, 1994.
4. ltoh N and Nagata S: A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 268: 10932-10937. 1993.
5. Chinnaiyan AM, O'Rourke K. Tewari M and Dixit VM: FADD. a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505-512, 1995.
6. Muzio M. Chinnaiyan AM. Kischkel FC. O'Rourke K, Shevchenko A. Ni J. Scaffidi C. Bretz JD. Zhang M, Gentz R. Mann M. Krammer PH. Peter ME and Dixit VM: FLICE. a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-l) death-inducing signaling complex. Cell 85: 817-827. 1996.
7. Medema JP. Scaffidi C. Kischkel FC. Shevchenko A, Mann M. Krammer PH and Peter ME: FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 16: 2794-2804. 1997.
8. Watanabe-Fukunaga R. Brannan Cl. Copeland NG, Jenkins NA and Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356: 314-317. 1992.
9. Straus SE. Sneller M. Lenardo MJ. Puck JM and Strober W: An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferalive syndrome. Ann Intern Med 130: 591-601. 1999.
10. Suda T. Takahashi T. Golstein P and Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75: 1169-1178. 1993.
11. Arase H. Arase N and Sailo T: Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 181: 1235-1238. 1995.
12. Inaba H and Komada Y: Resistant mechanisms of Fas (CD95)- nicdialed apoptosis in hematopoietic cells. Recent Res Dev Immunol 1:463-481, 1999.
13. Cheng J. Zhou T. Liu C. Shapiro JP. Brauer MJ, Kiefer MC, Barr PJ and Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263: 1759-1762. 1994.
14. Inaba H. Komada Y. Li QS, Zhang XL. Tanaka S. Azuma E. Yamamoto II and Sakurai M: mRNA expression of variant Fas molecules in acute leukemia cells. Am J Hematol 62: 150-158, 1999.
15. Midis GP. Shen Y and Owen-Sehaub LB: Elevated soluble Fas (sFas) levels in non-hematopoietic human malignancy. Cancer Res 56: 3870-3874. 1996.
16. Sato T. Irie S. Kitada S and Reed JC: FAP-I: a protein tyrosine phosphatase that associates with Fas. Science 268: 411-415, 1995.
17. Itoh N. Tsujimoto Y and Nagata S: Effect of bel-2 on Fas antigen-mediated cell death. J Immunol 151: 621-627. 1993.
18. Irmler M. Thome M. Hahnc M, Schneider P. Hofmann K. Steiner V. Bodmer JL. Schroter M. Burns K, Maltmann C. Rimoldi D. French LE and Tschopp J: Inhibition of death receptor signals by cellular FLIP. Nature 388: 190-195, 1997.
19. Deveraux QL. Roy N. Siennickc HR. van Arsdale T. Zhou Q. Srinivasula SM. Alnemri ES. Salvesen GS and Reed JC: lAPs block apoptolic events induced by caspasc-8 and cytochrome e by direct inhibition of distinct caspases. EMBO J 17: 2215-2223. 1998.
20. Mullauer L. Gruber P. Scbinger D. Buch J. Wohlfart S and Chou A: Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutat Res 488: 211-231.2001.
21. Inaba H. Glibctic M. Buck S. Ravindranath Y and Kaplan J: Interferon-Y sensitizes osteosarcoma cells to Fas-induced apoptosis by up-regulating Fas Receptors and caspase-8. Pediatr Blood Cancer43: 729-736. 2004.
22. Pitti RM, Marsters SA. Lawrence DA. Roy M. Kischkel FC. Dowd P. Huang A. Donahue CJ. Sherwood SW, Baldwin DT, Godowski PJ. Wood WI, Gurney AL. Hillan KJ. Cohen RL. Goddard AD, Bolstein D and Ashkenazi A: Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396: 699-703. 1998.
23. Barnhart BC, Alappat EC and Peter ME: The CD95 type l/type II model. Semin Immunol 15: 185-193. 2003.
24. Martin DA. Zheng L. Siegel RM. Huang B. Fisher GH. Wang J. Jackson CE. Puck JM. Dale J, Straus SE. Peter ME, Krammer PH. Fesik S and Lenardo MJ: Defective CD95/APO-l/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type la. Proc Natl Acad Sci USA 96: 4552-4557. 1999.
25. Landowski TH. Qu N. Buyuksal I. Painter JS and Dalton WS: Mutations in the Fas antigen in patients with multiple myeloma. Blood 90: 4266-4270. 1997.
26. Gronbaek K, Straten PT. Ralfkiaer E. Ahrenkiel V. Andersen MK. Hansen NE. Zeuthen J. Hou-Jensen K and Guldberg P: Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 92: 3018-3024. 1998.
27. Muschen M. Re D. Brauninger A. Wolf J. Hansntann ML. Diehl V. Kuppers R and Rajcwsky K: Somatic mutations of the CD95 gene in Hodekin and Recd-Slernberg cells. Cancer Res 60: 5640-5643. 2000.
28. Takakuwa T. Dong Z. Nakalsuka S, Kojya S. Harabuchi Y. Yang WI. Nagata S and Aozasa K: Frequent mutations of Fas gene in nasal NK/T cell lymphoma. Oncogene 21: 4702-4705. 2002.
29. Van Doom R. Dijkman R. Vermeer MH. Starink TM. Willemze R and Tensen CP: A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res 62: 5389-5392, 2002.
30. Lee SH. Shin MS. Park WS. Kim SY. Dong SM. Pi JH. Lee HK. Kim HS. Jang JJ. Kim CS. Kim SH. Lee JY and Yoo NJ: Alterations of Fas (APO-I/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res 59: 3068-3072. 1999.
31. Takayama H. Takakuwa T. Tsujimoto Y. Tani Y, Nonomura N. Okuyama A. Nagata S and Aozasa K: Frequent Fas gene mutations in testicular germ cell tumors. Am J Pathol 161: 635-641.2002.
32. Bellinger C. Bohler T. Karawajew L. Ludwig WD. Schrappe M and Debatin KM: Mutation analysis of CD95 (APO-l/Fas) in childhood B-lineage acute lymphoblastic leukaemia. Br J Haematol 102: 722-728. 1998.
33. Bellinger C. Kurz E. Bohler T. Schrappe M. Ludwig WD and Debatin KM: CD95 (APO-l/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood 91: 3943-3951, 1998.
34. Tamiya S. Etoh K. Suzushima H. Takatsuki K and Matsuoka M: Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood 91: 3935-3942. 1998.
35. Maeda T. Yamada Y. Moriuchi R. Sugahara K. Tsuruda K. Joh T. Atogami S. Tsukasaki K. Tomonaga M and Kamihira S: Fas gene mutation in the progression of adult T cell leukemia. J Exp Med 189: 1063-1071. 1999.
36. Schmaltz C. Alpdogan O. Homdasch KJ. Muriglan SJ. Kappel BJ. Teshima T, Ferrara JL. Burakoff SJ and van den Brink MR: Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in grafi-versus-hosl disease and graft-versus-leukemia effect. Blood 97: 2886-2895. 2001.